XOMA Ltd. ( NASDAQ: XOMA ) is a Berkeley, California-based biopharmaceutical
company, focusing on the discovery, development and manufacturing of therapeutic
antibodies designed to treat inflammatory, autoimmune, infectious and
oncological diseases. Last month, the company announced additional positive
results from an open-label pilot study of XOMA 052 in patients with uveitis of
Bechet's disease. The small cap stock of XOMA has a 52-week range of
$2.24-$12.60. Year-to-date, the stock is down 34.36%. Peregrine Pharmaceuticals
( NASDAQ: PPHM ) is a Tustin, California-based clinical-stage biopharmaceutical
company, engaged in the development of monoclonal antibodies for the treatment
of cancer and viral infections. Peregrine last week announced the completion of
last patient in Phase 2 Coatra® brain cancer trial. Since the announcement, the
small cap stock of Peregrine is up 34.94%. Year-to-date, the stock is down
24.32%. Nymox Pharmaceutical Corporation ( NASDAQ: NYMX ) is a Canada-based
biopharmaceutical company. Last week, Singular Research issued a new report on
Nymox, with a Buy rating and a 12-month price target of $14.50. The research
report mentioned that the announcement of marketing agreement for NX-1209 to
cover Europe, Middle East, Russia and parts of Africa. The small cap stock of
Nymox has a 52-week range of $2.64-$7.76. Year-to-date, the stock is up 51.32%.
Teva Pharmaceutical Industries Ltd. (ADR) ( NASDAQ: TEVA ) is an Israel-based
global pharmaceutical company, engaged in the development, production and
marketing of generic drugs covering all treatment categories. Teva announced
last week that it received a Complete Response Letter (CRL) from the U.S. FDA
for its supplemental New Drug Application (NDA) for lower-volume injection of
glatiramer acetate. Teva ADRs have a 52-week range of $46.99-$64.95.
Year-to-date, the ADRs are down 7.99%. Pfizer Inc. ( NYSE: PFE ) is a New York
City-based biopharmaceutical company. Last week, Pfizer announced the submission
of supplemental applications to both the U.S. FDA and the European Medicines
Agency (EMA) to expand the use of Prevnar 13® to adults 50-years of age and
older. The Pfizer stock has a 52-week range of $14-$20.36. Year-to-date, the
stock is down 3.74%. This corporate profile is provided for information purposes
only and should not be used as the basis for any investment decision. We are
neither licensed nor qualified to provide investment advice. We were not paid,
nor do we hold a position in these stocks. We reserve the right to buy or sell
XOMA, PPHM, NYMX, TEVA and PFE at any time after this post.
